Endo Health Solutions (Nasdaq: ENDP) is expected to report Q4 earnings on Feb. 28. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Endo Health Solutions's revenues will increase 0.5% and EPS will increase 10.0%.

The average estimate for revenue is $807.8 million. On the bottom line, the average EPS estimate is $1.54.

Revenue details
Last quarter, Endo Health Solutions logged revenue of $750.5 million. GAAP reported sales were 1.1% lower than the prior-year quarter's $759.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $1.28. GAAP EPS of $0.45 for Q3 were 32% higher than the prior-year quarter's $0.34 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 60.8%, 60 basis points better than the prior-year quarter. Operating margin was 27.6%, 380 basis points better than the prior-year quarter. Net margin was 7.2%, 180 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $3.03 billion. The average EPS estimate is $4.96.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 424 members out of 444 rating the stock outperform, and 20 members rating it underperform. Among 142 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 137 give Endo Health Solutions a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Health Solutions is outperform, with an average price target of $40.89.